Business / Finance

RSS

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals AG today announced that it has acquired the exclusive rights to market Daraprim (pyrimethamine) in the U.S. from Impax Laboratories, Inc. The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in the development of new drug candidates for toxoplasmosis.

10 Aug 2015

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Sorrento Therapeutics, Inc. announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two privately-held biotechnology companies.

10 Aug 2015

Turing Pharmaceuticals completes $90 million Series A financing

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on discovering and developing treatments for serious and life-threatening diseases, today announced the completion of its Series A financing. The $90 million round was led by Martin Shkreli, Founder & Chief Executive Officer.

10 Aug 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

GenVec reports net loss of $1.9 million for second quarter 2015

GenVec, Inc. today reported financial results for the second quarter ended June 30, 2015. For the three months ended June 30, 2015, GenVec reported a net loss of $1.9 million, or $0.11 per share, on revenues of $0.1 million, compared with a net loss of $1.7 million, or $0.10 per share, on revenues of $0.1 million, for the same period in the prior year.

7 Aug 2015

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.

7 Aug 2015

Hill-Rom Holdings' revenue increases 19% to $475 million in third quarter 2015

Hill-Rom Holdings, Inc. announced financial results for its third quarter ended June 30, 2015 and updated its 2015 financial outlook. Adjusted earnings per diluted share of $0.62 increased 5 percent from $0.59 in the prior year, while reported earnings per diluted share of $0.33 decreased from $0.45. Adjustments to reported earnings are detailed in the reconciliation schedules provided.

7 Aug 2015

Curo Consulting receive Queen’s Award for Enterprise

Tech Company Curo Consulting have received the highest accolade given to British business. In July, Her Majesty’s representative, the Lord Lieutenant of Buckinghamshire, Sir Henry Aubrey-Fletcher visited Curo Consulting’s offices in Marlow to present the award in person. The team were also invited to attend a reception at Buckingham palace.

6 Aug 2015

Neovasc's second quarter revenues drop 18%

Neovasc Inc. today announced financial results for the quarter ended June 30, 2015.

6 Aug 2015

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva Biosciences, Inc. (formerly Hera Therapeutics), a biopharmaceutical company developing antiviral therapeutics, today announced that it has raised $16 million in a Series B financing, its first institutional round.

6 Aug 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

BD reports adjusted revenues of $3.133 billion for third fiscal quarter 2015

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly adjusted revenues of $3.133 billion for the third fiscal quarter ended June 30, 2015, an increase of 45.2 percent over the prior-year period as reported, or 55.6 percent on a currency-neutral basis. On a comparable, currency-neutral basis, adjusted revenues grew 2.4 percent. As reported, revenues were $3.120 billion.

From BD (Becton, Dickinson and Company) 6 Aug 2015

WI Harper Group announces investment in Cold Genesys

WI Harper Group, a leading US & China, cross-border early growth and expansion stage venture capital firm, today announced an investment in Cold Genesys Inc, a clinical-stage privately-held biotech company developing oncolytic immunotherapies for cancer.

6 Aug 2015

Delcath Systems achieves record quarterly product revenue in Q2 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2015.

5 Aug 2015

Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cardiome Pharma Corp. today reported financial results for the second quarter and six months ended June 30, 2015. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP).

5 Aug 2015

Health Care DataWorks acquired by Health Catalyst

Health Catalyst, a leader in healthcare data warehousing, analytics and outcomes improvement, announced today that it has acquired Health Care DataWorks (HCD), a leading provider of business intelligence for health systems.

5 Aug 2015

LifeBond announces closure of $27M Series D preferred equity investment

LifeBond, a leader in the development of bio-surgical medical devices for tissue repair, announced today it has closed a $27M Series D preferred equity investment. Participants in the round include Pitango Venture Capital, Adams Street Partners, Sino Biopharmaceutical Ltd., and all existing investors.

5 Aug 2015

Leidos Holdings reports strong financial results in Q2 2015

Leidos Holdings, Inc., a national security, health and engineering solutions company, today reported financial results for the second quarter of calendar year 2015.

5 Aug 2015

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).

5 Aug 2015

Quest Diagnostics acquires laboratory outreach service business of MemorialCare Health System

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has completed the previously announced acquisition of MemorialCare Health System's laboratory outreach service business.

From Quest Diagnostics 4 Aug 2015